U.S. argues drug company harms from IRA are speculative

[Editor’s Note: Attorneys for the Department of Justice and the U.S. Chamber of Commerce presented arguments on Sept. 15. Oral arguments were consistent with the arguments summarized in BioCentury’s Sept. 14 story.]

Oral arguments Friday in litigation filed by the U.S. Chamber of Commerce seeking an injunction to prevent implementation of the Medicare drug price negotiation program are likely to center on questions of standing and ripeness, along with the U.S. government’s contention that claims that the law harms the plaintiffs are speculative. ...